JP2016516043A5 - - Google Patents

Download PDF

Info

Publication number: JP2016516043A5
Authority: JP; Japan
Prior art keywords: optionally substituted; compound; optionally; compound according; branched
Prior art date: 2014-03-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP2016502444A

Other languages

English (en)

Japanese (ja)

Other versions

JP6562898B2 (ja

JP2016516043A (ja

Filing date

2014-03-14

Publication date

2017-04-13

2014-03-14 Application filed filed Critical

2014-03-14 Priority claimed from PCT/US2014/027449 external-priority patent/WO2014152536A2/en

2016-06-02 Publication of JP2016516043A publication Critical patent/JP2016516043A/ja

2017-04-13 Publication of JP2016516043A5 publication Critical patent/JP2016516043A5/ja

2019-08-21 Application granted granted Critical

2019-08-21 Publication of JP6562898B2 publication Critical patent/JP6562898B2/ja

Status Active legal-status Critical Current

2034-03-14 Anticipated expiration legal-status Critical

Links

150000001875 compounds Chemical class 0.000 claims 34
239000001257 hydrogen Substances 0.000 claims 12
229910052739 hydrogen Inorganic materials 0.000 claims 12
125000001072 heteroaryl group Chemical group 0.000 claims 11
125000000217 alkyl group Chemical group 0.000 claims 8
150000002431 hydrogen Chemical class 0.000 claims 8
125000006710 (C2-C12) alkenyl group Chemical group 0.000 claims 7
125000006711 (C2-C12) alkynyl group Chemical group 0.000 claims 7
125000005843 halogen group Chemical group 0.000 claims 7
125000000623 heterocyclic group Chemical group 0.000 claims 7
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
125000004450 alkenylene group Chemical group 0.000 claims 5
125000002947 alkylene group Chemical group 0.000 claims 5
125000004419 alkynylene group Chemical group 0.000 claims 5
239000000203 mixture Substances 0.000 claims 5
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
125000004093 cyano group Chemical group *C#N 0.000 claims 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
125000004433 nitrogen atom Chemical group N* 0.000 claims 4
125000003107 substituted aryl group Chemical group 0.000 claims 4
241000124008 Mammalia Species 0.000 claims 3
125000003118 aryl group Chemical group 0.000 claims 3
125000004076 pyridyl group Chemical group 0.000 claims 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
201000010099 disease Diseases 0.000 claims 2
208000035475 disorder Diseases 0.000 claims 2
125000002541 furyl group Chemical group 0.000 claims 2
125000002971 oxazolyl group Chemical group 0.000 claims 2
239000008194 pharmaceutical composition Substances 0.000 claims 2
125000000547 substituted alkyl group Chemical group 0.000 claims 2
125000000335 thiazolyl group Chemical group 0.000 claims 2
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 1
208000023275 Autoimmune disease Diseases 0.000 claims 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
239000005977 Ethylene Substances 0.000 claims 1
102000004157 Hydrolases Human genes 0.000 claims 1
108090000604 Hydrolases Proteins 0.000 claims 1
150000001204 N-oxides Chemical class 0.000 claims 1
230000001668 ameliorated effect Effects 0.000 claims 1
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
230000000694 effects Effects 0.000 claims 1
125000001153 fluoro group Chemical group F* 0.000 claims 1
125000001188 haloalkyl group Chemical group 0.000 claims 1
125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
208000027866 inflammatory disease Diseases 0.000 claims 1
230000005764 inhibitory process Effects 0.000 claims 1
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 1
229910052757 nitrogen Inorganic materials 0.000 claims 1
125000004043 oxo group Chemical group O=* 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 claims 1
239000000651 prodrug Substances 0.000 claims 1
229940002612 prodrug Drugs 0.000 claims 1
125000003226 pyrazolyl group Chemical group 0.000 claims 1
150000003839 salts Chemical class 0.000 claims 1
239000012453 solvate Substances 0.000 claims 1
-1 substituted Chemical class 0.000 claims 1
125000001544 thienyl group Chemical group 0.000 claims 1
125000001425 triazolyl group Chemical group 0.000 claims 1
0 *C(*)(*)N(*)*c1ccccc1 Chemical compound *C(*)(*)N(*)*c1ccccc1 0.000 description 16
WHELBNUVILHIHT-UHFFFAOYSA-N Cc(cc1)ccc1-c1ncc[o]1 Chemical compound Cc(cc1)ccc1-c1ncc[o]1 WHELBNUVILHIHT-UHFFFAOYSA-N 0.000 description 8
DXYYSGDWQCSKKO-UHFFFAOYSA-N Cc1nc2ccccc2[s]1 Chemical compound Cc1nc2ccccc2[s]1 DXYYSGDWQCSKKO-UHFFFAOYSA-N 0.000 description 3
FKWHHXZNCQKLJG-UHFFFAOYSA-N CNCc(cccn1)c1Oc(cc1)ccc1C(O)=O Chemical compound CNCc(cccn1)c1Oc(cc1)ccc1C(O)=O FKWHHXZNCQKLJG-UHFFFAOYSA-N 0.000 description 2
ALHUXMDEZNLFTA-UHFFFAOYSA-N Cc1nc2ccccc2nc1 Chemical compound Cc1nc2ccccc2nc1 ALHUXMDEZNLFTA-UHFFFAOYSA-N 0.000 description 2
WGTUMQXQVLOHQE-UHFFFAOYSA-N CCCN(C)Cc1cccnc1Oc(cc1)ccc1C(OCC)=O Chemical compound CCCN(C)Cc1cccnc1Oc(cc1)ccc1C(OCC)=O WGTUMQXQVLOHQE-UHFFFAOYSA-N 0.000 description 1
VGZHYZHNXNVWHH-UHFFFAOYSA-N CCCNCc(cc1)cnc1-[n]1c(C)c(C(O)=O)nc1 Chemical compound CCCNCc(cc1)cnc1-[n]1c(C)c(C(O)=O)nc1 VGZHYZHNXNVWHH-UHFFFAOYSA-N 0.000 description 1
QEYUNVXPSOCBAG-UHFFFAOYSA-N CCNCc1cccnc1Oc1cc(C(O)=O)ccc1 Chemical compound CCNCc1cccnc1Oc1cc(C(O)=O)ccc1 QEYUNVXPSOCBAG-UHFFFAOYSA-N 0.000 description 1
QMBLXRHXCGJOGU-UHFFFAOYSA-N CCc1ccc(CC(O)=O)cc1 Chemical compound CCc1ccc(CC(O)=O)cc1 QMBLXRHXCGJOGU-UHFFFAOYSA-N 0.000 description 1
BHIQFQYCZIJUIG-UHFFFAOYSA-N CCc1ccc(CC(OC)=O)cc1 Chemical compound CCc1ccc(CC(OC)=O)cc1 BHIQFQYCZIJUIG-UHFFFAOYSA-N 0.000 description 1
OLPWVSINLQYDIY-UHFFFAOYSA-N CN(C)Cc(cccn1)c1Oc(cc1)ccc1C(O)=O Chemical compound CN(C)Cc(cccn1)c1Oc(cc1)ccc1C(O)=O OLPWVSINLQYDIY-UHFFFAOYSA-N 0.000 description 1
YMXQNJHJWAVADX-UHFFFAOYSA-N CN(C)Cc1ccc(N(CC2)CCC2C(O)=O)nc1 Chemical compound CN(C)Cc1ccc(N(CC2)CCC2C(O)=O)nc1 YMXQNJHJWAVADX-UHFFFAOYSA-N 0.000 description 1
JBOVVZBMLVRDAP-UHFFFAOYSA-N CN(CCOC)Cc(cccc1)c1Oc1cccc(C(O)=O)c1 Chemical compound CN(CCOC)Cc(cccc1)c1Oc1cccc(C(O)=O)c1 JBOVVZBMLVRDAP-UHFFFAOYSA-N 0.000 description 1
LJVIXOQEJPEWJW-UHFFFAOYSA-N CNCc(cc1)cnc1NCCC(O)=O Chemical compound CNCc(cc1)cnc1NCCC(O)=O LJVIXOQEJPEWJW-UHFFFAOYSA-N 0.000 description 1
YCESUPDCBCISGX-UHFFFAOYSA-N CNCc(cccn1)c1Oc(ccc(C(O)=O)c1)c1OC Chemical compound CNCc(cccn1)c1Oc(ccc(C(O)=O)c1)c1OC YCESUPDCBCISGX-UHFFFAOYSA-N 0.000 description 1
VYMYSBRLXXKRPA-UHFFFAOYSA-N CNCc1ccc(N(C)CC(O)=O)nc1 Chemical compound CNCc1ccc(N(C)CC(O)=O)nc1 VYMYSBRLXXKRPA-UHFFFAOYSA-N 0.000 description 1
RPLYIPWVKQPFFL-UHFFFAOYSA-N CNCc1ccc(NCc(cc2)ccc2C(O)=O)nc1 Chemical compound CNCc1ccc(NCc(cc2)ccc2C(O)=O)nc1 RPLYIPWVKQPFFL-UHFFFAOYSA-N 0.000 description 1
UDOMVKIVDINFMC-UHFFFAOYSA-N COC(c1ccc(CSC)cc1)=O Chemical compound COC(c1ccc(CSC)cc1)=O UDOMVKIVDINFMC-UHFFFAOYSA-N 0.000 description 1
GHPODDMCSOYWNE-UHFFFAOYSA-N Cc(cc1)cc2c1OCO2 Chemical compound Cc(cc1)cc2c1OCO2 GHPODDMCSOYWNE-UHFFFAOYSA-N 0.000 description 1
LNJMHEJAYSYZKK-UHFFFAOYSA-N Cc1ncccn1 Chemical compound Cc1ncccn1 LNJMHEJAYSYZKK-UHFFFAOYSA-N 0.000 description 1
KCTZYAAHUYSVON-UHFFFAOYSA-N OC(c1ccc(CS)cc1)=O Chemical compound OC(c1ccc(CS)cc1)=O KCTZYAAHUYSVON-UHFFFAOYSA-N 0.000 description 1

JP2016502444A 2013-03-14 2014-03-14 ロイコトリエンａ４加水分解酵素の阻害剤 Active JP6562898B2 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201361781168P	2013-03-14	2013-03-14
US61/781,168		2013-03-14
PCT/US2014/027449 WO2014152536A2 (en)	2013-03-14	2014-03-14	Inhibitors of leukotriene a4 hydrolase

Publications (3)

Publication Number	Publication Date
JP2016516043A JP2016516043A (ja)	2016-06-02
JP2016516043A5 true JP2016516043A5 (2)	2017-04-13
JP6562898B2 JP6562898B2 (ja)	2019-08-21

Family

ID=51581719

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2016502444A Active JP6562898B2 (ja)	2013-03-14	2014-03-14	ロイコトリエンａ４加水分解酵素の阻害剤

Country Status (10)

Country	Link
US (2)	US9822106B2 (2)
EP (1)	EP2968265A4 (2)
JP (1)	JP6562898B2 (2)
KR (1)	KR20150131211A (2)
AU (2)	AU2014239585B2 (2)
BR (1)	BR112015022227A2 (2)
CA (1)	CA2906086A1 (2)
MX (1)	MX2015011676A (2)
RU (1)	RU2690489C2 (2)
WO (1)	WO2014152536A2 (2)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
LT1976828T (lt)	2005-12-29	2017-04-25	Celtaxsys, Inc.	Diamino dariniai, kaip leukotrieno a4 hidrolazės inhibitoriai
AU2014249168B2 (en)	2013-03-12	2018-07-12	Celltaxis, Llc	Methods of inhibiting leukotriene A4 hydrolase
CA2906035A1 (en)	2013-03-14	2014-09-25	Celtaxsys, Inc.	Inhibitors of leukotriene a4 hydrolase
BR112015022864A8 (pt)	2013-03-14	2019-11-26	Celtaxsys Inc	composto, composição farmacêutica e uso dos mesmos
WO2017070089A1 (en)	2015-10-19	2017-04-27	Incyte Corporation	Heterocyclic compounds as immunomodulators
SG10202004618TA (en)	2015-11-19	2020-06-29	Incyte Corp	Heterocyclic compounds as immunomodulators
MA44075A (fr)	2015-12-17	2021-05-19	Incyte Corp	Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
TWI773657B (zh)	2015-12-18	2022-08-11	美商亞德利克斯公司	作爲非全身ｔｇｒ５促效劑之經取代之4-苯基吡啶化合物
US12084472B2 (en)	2015-12-18	2024-09-10	Ardelyx, Inc.	Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
AU2016379372A1 (en)	2015-12-22	2018-08-02	Incyte Corporation	Heterocyclic compounds as immunomodulators
AR108396A1 (es)	2016-05-06	2018-08-15	Incyte Corp	Compuestos heterocíclicos como inmunomoduladores
WO2017205464A1 (en)	2016-05-26	2017-11-30	Incyte Corporation	Heterocyclic compounds as immunomodulators
HUE060256T2 (hu)	2016-06-20	2023-02-28	Incyte Corp	Heterociklusos vegyületek mint immunmodulátorok
EP3484866B1 (en)	2016-07-14	2022-09-07	Incyte Corporation	Heterocyclic compounds as immunomodulators
WO2018044783A1 (en)	2016-08-29	2018-03-08	Incyte Corporation	Heterocyclic compounds as immunomodulators
US10385007B2 (en)	2016-12-09	2019-08-20	Celtaxsys, Inc.	Monamine and monoamine derivatives as inhibitors of leukotriene A4 hydrolase
LT3558990T (lt)	2016-12-22	2022-12-27	Incyte Corporation	Tetrahidroimidazo[4,5-c]piridino dariniai kaip pd-l1 internalizavimo induktoriai
US20180179202A1 (en)	2016-12-22	2018-06-28	Incyte Corporation	Heterocyclic compounds as immunomodulators
ES2874756T3 (es)	2016-12-22	2021-11-05	Incyte Corp	Derivados de triazolo[1,5-A]piridina como inmunomoduladores
WO2018119221A1 (en)	2016-12-22	2018-06-28	Incyte Corporation	Pyridine derivatives as immunomodulators
JP7101678B2 (ja)	2016-12-22	2022-07-15	インサイト・コーポレイション	免疫調節剤としての複素環式化合物
WO2019036024A1 (en)	2017-08-17	2019-02-21	Bristol-Myers Squibb Company	2- (1,1'-BIPHENYL) -1H-BENZO [D] IMIDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS AGONISTS OF APELIN AND APJ FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
US10925851B2 (en)	2018-03-15	2021-02-23	Regents Of The University Of Minnesota	Use of Tosedostat and related compounds as analgesics
SMT202500157T1 (it)	2018-03-30	2025-05-12	Incyte Corp	Composti eterociclici come immunomodulatori
HUE061503T2 (hu)	2018-05-11	2023-07-28	Incyte Corp	Tetrahidro-imidazo[4,5-C]piridin-származékok mint PD-L1 immunmodulátorok
ES3014615T3 (en)	2018-05-31	2025-04-23	Celltaxis Llc	Method of reducing pulmonary exacerbations in respiratory disease patients
JP7665593B2 (ja)	2019-08-09	2025-04-21	インサイト・コーポレイション	Ｐｄ－１／ｐｄ－ｌ１阻害剤の塩
PE20221038A1 (es)	2019-09-30	2022-06-17	Incyte Corp	Compuestos de pirido[3,2-d] pirimidina como inmunomoduladores
CA3160131A1 (en)	2019-11-11	2021-05-20	Incyte Corporation	Salts and crystalline forms of a pd-1/pd-l1 inhibitor
JP7545570B2 (ja)	2020-08-14	2024-09-04	ノバルティスアーゲー	ヘテロアリール置換スピロピペリジニル誘導体及びその薬学的使用
WO2022099018A1 (en)	2020-11-06	2022-05-12	Incyte Corporation	Process of preparing a pd-1/pd-l1 inhibitor
TW202233615A (zh)	2020-11-06	2022-09-01	美商英塞特公司	Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式
CR20230230A (es)	2020-11-06	2023-07-27	Incyte Corp	Proceso para hacer un inhibidor de pd-1/pdl1 y sales y formas cristalinas del mismo

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL6815872A (2) *	1967-11-22	1969-05-27
US4582833A (en)	1984-04-16	1986-04-15	American Cyanamid Company	2-(substituted-1-piperazinyl)[1,2,4]triazolo[1,5-a]pyrimidines
US4576943A (en)	1984-10-09	1986-03-18	American Cyanamid Company	Pyrazolo[1,5-a]pyrimidines
US5308852A (en)	1992-06-29	1994-05-03	Merck Frosst Canada, Inc.	Heteroarylnaphthalenes as inhibitors of leukotriene biosynthesis
US5631401A (en) *	1994-02-09	1997-05-20	Abbott Laboratories	Inhibitors of protein farnesyltransferase and squalene synthase
KR970706242A (ko) *	1994-10-04	1997-11-03	후지야마 아키라	우레아 유도체 및 ACAT-억제제로서 그의 용도(Urea derivatives and their use as ACAT-inhibitors)
US6506876B1 (en) *	1994-10-11	2003-01-14	G.D. Searle & Co.	LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use
DK0880363T3 (da)	1996-02-13	2003-01-20	Searle & Co	Kombinationer der omfatter en cyclooxygenase-2 hæmmer samt en leukotrien A4 hydrolasehæmmer, som har immunsuppressive virkninger
US5925654A (en) *	1997-03-12	1999-07-20	G.D. Searle & Co.	LTA4 , hydrolase inhibitors
US6309561B1 (en)	1997-12-24	2001-10-30	3M Innovative Properties Company	Liquid crystal compounds having a chiral fluorinated terminal portion
US6380203B1 (en)	1998-01-14	2002-04-30	Merck & Co., Inc.	Angiogenesis inhibitors
US6096745A (en) *	1998-03-25	2000-08-01	Bristol-Myers Squibb Co.	Imidazolone anorectic agents: III. heteroaryl derivatives
GB9815880D0 (en)	1998-07-21	1998-09-16	Pfizer Ltd	Heterocycles
GB9919776D0 (en)	1998-08-31	1999-10-27	Zeneca Ltd	Compoujnds
AR023659A1 (es)	1998-09-18	2002-09-04	Vertex Pharma	Un compuesto inhibidor de p38, una composicion farmaceutica que lo comprende y el uso de dicha composicion en el tratamiento y prevencion de estados patologicos
DE60023492T2 (de) *	1999-05-17	2006-07-20	Novo Nordisk A/S	Glucagon antagonisten/inverse agonisten
US6699873B1 (en)	1999-08-04	2004-03-02	Millennium Pharmaceuticals, Inc.	Melanocortin-4 receptor binding compounds and methods of use thereof
US6924313B1 (en) *	1999-09-23	2005-08-02	Pfizer Inc.	Substituted tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
US6800651B2 (en) *	2000-02-03	2004-10-05	Eli Lilly And Company	Potentiators of glutamate receptors
US6451798B2 (en)	2000-02-22	2002-09-17	Cv Therapeutics, Inc.	Substituted alkyl piperazine derivatives
US6552023B2 (en)	2000-02-22	2003-04-22	Cv Therapeutics, Inc.	Aralkyl substituted piperazine compounds
JP2001354657A (ja)	2000-06-09	2001-12-25	Sds Biotech:Kk	置換ピペラジン誘導体及び農園芸用殺菌剤
US6875483B2 (en)	2000-07-06	2005-04-05	Fuji Photo Film Co., Ltd.	Liquid crystal composition comprising liquid crystal molecules and alignment promoter
WO2002064211A1 (en)	2001-02-09	2002-08-22	Merck & Co., Inc.	Thrombin inhibitors
CA2439415C (en)	2001-03-02	2011-09-20	Merck Frosst Canada & Co.	Cathepsin cysteine protease inhibitors
AUPR362001A0 (en)	2001-03-08	2001-04-05	Fujisawa Pharmaceutical Co., Ltd.	New compound
FR2826011B1 (fr)	2001-06-14	2004-12-10	Oreal	Nouveaux derives de la 7-oxo-dhea et utilisation cosmetique
SE0102616D0 (sv)	2001-07-25	2001-07-25	Astrazeneca Ab	Novel compounds
BR0212512A (pt)	2001-09-14	2004-10-26	Tularik Inc	Composto, composição farmacêutica e métodos para tratar um distúrbio, condição ou doença, elevar os nìveis do colesterol hdl, reduzir os nìveis de triglicerìdeo, tratar diabete, diminuir a resistência à insulina ou diminuir a pressão arterial e modular a ppardelta
WO2003037271A2 (en)	2001-10-30	2003-05-08	Millennium Pharmaceuticals,Inc.	Compounds, pharmaceutical compositions and methods of use therefor
EP1501514B1 (en) *	2002-05-03	2012-12-19	Exelixis, Inc.	Protein kinase modulators and methods of use
KR101025633B1 (ko) *	2002-09-19	2011-03-30	일라이 릴리 앤드 캄파니	오피오이드 수용체 안타고니스트로서의 디아릴 에테르
WO2005027886A2 (en)	2003-09-17	2005-03-31	Decode Genetics Ehf.	Methods of preventing or treating recurrence of myocardial infarction
CA2502359A1 (en)	2002-10-17	2004-04-29	Decode Genetics Ehf.	Susceptibility gene for myocardial infarction
US7851486B2 (en)	2002-10-17	2010-12-14	Decode Genetics Ehf.	Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
WO2004058683A2 (en) *	2002-12-20	2004-07-15	Migenix Corp.	Ligands of adenine nucleotide translocase (ant) and compositions and methods related thereto
EP1611902A4 (en)	2003-04-03	2006-04-12	Kyowa Hakko Kogyo Kk	MEANS FOR THE PREVENTION AND / OR TREATMENT OF NEUROPATHIC PAIN
US7115642B2 (en)	2003-05-02	2006-10-03	Rigel Pharmaceuticals, Inc.	Substituted diphenyl isoxazoles, pyrazoles and oxadiazoles useful for treating HCV infection
JP2005008581A (ja)	2003-06-20	2005-01-13	Kissei Pharmaceut Co Ltd	新規なピラゾロ［１，５−ａ］ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
ATE403654T1 (de) *	2003-07-28	2008-08-15	Janssen Pharmaceutica Nv	Benzimidazol-, benzothiazol- und benzoxazolderivate und deren verwendung als lta4h-modulatoren
WO2005033079A1 (ja) *	2003-09-30	2005-04-14	Eisai Co., Ltd.	ヘテロ環化合物を含有する新規な抗真菌剤
DE10356579A1 (de)	2003-12-04	2005-07-07	Merck Patent Gmbh	Aminderivate
SE0303480D0 (sv)	2003-12-19	2003-12-19	Biovitrum Ab	Benzofuranes
DE602005015682D1 (de)	2004-02-04	2009-09-10	Neurosearch As	Dimere azacyclische verbindungen und deren verwendung
WO2006033795A2 (en)	2004-09-17	2006-03-30	Wyeth	Substituted pyrazolo [1, 5-a] pyrimidines for inhibiting abnormal cell growth
CA2603122A1 (en)	2005-03-31	2006-10-05	Janssen Pharmaceutica N.V.	Phenyl and pyridyl lta4h modulators
JP2008540395A (ja) *	2005-05-03	2008-11-20	ファイザー・インク	アミドレソルシノール化合物
CA2610671A1 (en) *	2005-05-31	2006-12-07	Astrazeneca Ab	Novel mchr1 antagonists and their use for the treatment of mchr1 mediated conditions and disorders
GB0514018D0 (en)	2005-07-07	2005-08-17	Ionix Pharmaceuticals Ltd	Chemical compounds
JP5133889B2 (ja)	2005-09-21	2013-01-30	デコードジェネティクスイーエイチエフ	炎症治療のためのビアリール基置換複素環ｌｔａ４ｈ阻害剤
CN1947717B (zh)	2005-10-14	2012-09-26	卓敏	选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用
DE102005049954A1 (de)	2005-10-19	2007-05-31	Sanofi-Aventis Deutschland Gmbh	Triazolopyridin-derivate als Inhibitoren von Lipasen und Phospholipasen
LT1976828T (lt)	2005-12-29	2017-04-25	Celtaxsys, Inc.	Diamino dariniai, kaip leukotrieno a4 hidrolazės inhibitoriai
CN101379060B (zh)	2006-02-10	2012-05-23	转化技术制药公司	作为Aurora激酶抑制剂的苯并唑系衍生物、组合物和使用方法
EP1878730A1 (en) *	2006-07-12	2008-01-16	Bayer Schering Pharma Aktiengesellschaft	Substituted isoxazolines, pharmaceutical compositions containing the same, methods of preparing the same, and uses of the same
EP2058309A4 (en)	2006-08-04	2010-12-22	Takeda Pharmaceutical	CONDENSED HETEROCYCLIC COMPOUND
AU2007312389B2 (en)	2006-10-19	2012-02-23	F. Hoffmann-La Roche Ag	Aminomethyl-2-imidazoles with affinity with the trace amine associated receptors
SI2121636T1 (sl)	2006-12-14	2017-06-30	Janssen Pharmaceutica N.V.	Postopek za pripravo derivatov piperazinila in diazepanil benzamida
FR2911140B1 (fr)	2007-01-05	2009-02-20	Sanofi Aventis Sa	Nouveaux derives de 2-anilino 4-heteroaryle pyrimides, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
FR2911138B1 (fr)	2007-01-05	2009-02-20	Sanofi Aventis Sa	Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
FR2911139A1 (fr)	2007-01-05	2008-07-11	Sanofi Aventis Sa	Nouveaux derives de phenyl-(4-phenyl-pyrimidin-2-yl)amines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
CA2691662A1 (en)	2007-07-02	2009-01-08	F. Hoffmann-La Roche Ag	Imidazole derivatives as ccr2 receptor antagonists
JP5341084B2 (ja) *	2007-08-03	2013-11-13	エフ．ホフマン−ラロシュアーゲー	Ｔａａｒ１リガンドとしてのピリジンカルボキシアミド及びベンズアミド誘導体
US7902181B2 (en)	2007-12-12	2011-03-08	Astrazeneca Ab	Compounds 010
FR2928070A1 (fr) *	2008-02-27	2009-09-04	Sumitomo Chemical Co	Composition agricole, utilisation d'un compose pour sa production et procede pour matriser ou prevenir les maladies des plantes.
US20100029657A1 (en)	2008-02-29	2010-02-04	Wyeth	Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof
MY157597A (en) *	2008-04-11	2016-06-30	Janssen Pharmaceutica Nv	Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene a4 hydrolase
EP2110374A1 (en)	2008-04-18	2009-10-21	Merck Sante	Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
WO2010011912A1 (en)	2008-07-25	2010-01-28	Smithkline Beecham Corporation	Trpv4 antagonists
CN102030700B (zh) *	2009-09-30	2016-06-01	中国医学科学院药物研究所	苯甲酰胺基羧酸类化合物及其制法和药物用途
US8802694B2 (en)	2009-12-07	2014-08-12	Targacept, Inc.	3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetycholine receptor ligands
JP2013047189A (ja) *	2009-12-25	2013-03-07	Kyorin Pharmaceutical Co Ltd	新規パラバン酸誘導体及びそれらを有効成分とする医薬
PE20130774A1 (es)	2010-07-29	2013-06-26	Rigel Pharmaceuticals Inc	Compuestos heterociclicos activadores de ampk y metodos para emplearlos
CN103415513B (zh) *	2011-03-14	2016-01-20	勃林格殷格翰国际有限公司	白三烯产物的苯并二氧杂环己烷抑制剂
CA2829993A1 (en) *	2011-03-15	2012-09-20	Rib-X Pharmaceuticals, Inc.	Antimicrobial agents
US8748624B2 (en) *	2011-05-23	2014-06-10	Janssen Pharmaceutica Nv	Picolinamido-propanoic acid derivatives useful as glucagon receptor antagonists
US9006235B2 (en)	2012-03-06	2015-04-14	Bristol-Myers Squibb Company	Inhibitors of human immunodeficiency virus replication
AU2014249168B2 (en)	2013-03-12	2018-07-12	Celltaxis, Llc	Methods of inhibiting leukotriene A4 hydrolase
CA2906035A1 (en)	2013-03-14	2014-09-25	Celtaxsys, Inc.	Inhibitors of leukotriene a4 hydrolase
BR112015022864A8 (pt)	2013-03-14	2019-11-26	Celtaxsys Inc	composto, composição farmacêutica e uso dos mesmos

2014
- 2014-03-14 WO PCT/US2014/027449 patent/WO2014152536A2/en not_active Ceased
- 2014-03-14 MX MX2015011676A patent/MX2015011676A/es unknown
- 2014-03-14 BR BR112015022227A patent/BR112015022227A2/pt not_active Application Discontinuation
- 2014-03-14 AU AU2014239585A patent/AU2014239585B2/en not_active Ceased
- 2014-03-14 KR KR1020157028770A patent/KR20150131211A/ko not_active Ceased
- 2014-03-14 RU RU2015137977A patent/RU2690489C2/ru not_active IP Right Cessation
- 2014-03-14 CA CA2906086A patent/CA2906086A1/en not_active Abandoned
- 2014-03-14 JP JP2016502444A patent/JP6562898B2/ja active Active
- 2014-03-14 EP EP14769620.7A patent/EP2968265A4/en not_active Withdrawn
2015
- 2015-09-10 US US14/849,829 patent/US9822106B2/en not_active Expired - Fee Related
2017
- 2017-11-02 US US15/801,494 patent/US20180118735A1/en not_active Abandoned
2019
- 2019-07-02 AU AU2019204753A patent/AU2019204753A1/en not_active Abandoned

Publication	Publication Date	Title
JP2016516043A5 (2)	2017-04-13
JP2016513696A5 (2)	2017-04-13
JP2016513681A5 (2)	2017-04-13
JP2016506962A5 (2)	2017-03-02
JP2015522650A5 (2)	2016-09-15
JP2014503574A5 (2)	2015-02-26
JP2016506961A5 (2)	2017-03-02
JP2019501125A5 (2)	2019-12-26
JP2013542261A5 (2)	2014-12-25
JP2011513305A5 (2)	2012-04-05
JP2014506907A5 (2)	2015-04-16
JP2015537020A5 (2)	2018-02-01
JP2016526576A5 (2)	2018-05-31
JP2017509586A5 (2)	2018-01-11
JP2014506599A5 (2)	2015-03-19
RU2015146957A (ru)	2017-05-31	Производные доластатина 10 и ауристатинов
JP2013512903A5 (2)	2013-12-19
JP2015500887A5 (2)	2015-12-17
JP2017526677A5 (2)	2018-09-27
JP2017508782A5 (2)	2018-01-25
MX336505B (es)	2016-01-21	Metodos y composiciones para reducir la grasa y los adipocitos del cuerpo.
JP2014508804A5 (2)	2015-04-16
JP2018527295A5 (2)	2019-06-13
RU2017116196A (ru)	2018-12-14	2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1
JP2013523814A5 (2)	2014-05-22